KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moderna (MRNA) Receivables (2017 - 2025)

Moderna (MRNA) has disclosed Receivables for 9 consecutive years, with $410.0 million as the latest value for Q4 2025.

  • Quarterly Receivables fell 45.84% to $410.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $410.0 million through Dec 2025, down 45.84% year-over-year, with the annual reading at $410.0 million for FY2025, 45.84% down from the prior year.
  • Receivables for Q4 2025 was $410.0 million at Moderna, down from $1.0 billion in the prior quarter.
  • The five-year high for Receivables was $3.2 billion in Q4 2021, with the low at $83.0 million in Q2 2025.
  • Average Receivables over 5 years is $1.6 billion, with a median of $1.3 billion recorded in 2022.
  • The sharpest move saw Receivables skyrocketed 23031.11% in 2021, then crashed 89.12% in 2023.
  • Over 5 years, Receivables stood at $3.2 billion in 2021, then tumbled by 55.77% to $1.4 billion in 2022, then crashed by 33.36% to $951.0 million in 2023, then dropped by 20.4% to $757.0 million in 2024, then tumbled by 45.84% to $410.0 million in 2025.
  • According to Business Quant data, Receivables over the past three periods came in at $410.0 million, $1.0 billion, and $83.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.